ProQR Therapeutics Appoints New CFO
Ticker: PRQR · Form: 6-K · Filed: Dec 10, 2024 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, management-change, personnel
TL;DR
ProQR names Peter van der Kuy as new CFO starting Jan 1, 2025.
AI Summary
On December 10, 2024, ProQR Therapeutics N.V. announced the appointment of Peter van der Kuy as its new Chief Financial Officer, effective January 1, 2025. Van der Kuy previously served as CFO at Pharming Group N.V. and brings extensive financial leadership experience in the biopharmaceutical sector.
Why It Matters
The appointment of a new CFO is a significant leadership change that can impact financial strategy and investor confidence.
Risk Assessment
Risk Level: low — This filing is an announcement of a routine executive appointment and does not involve significant financial or operational changes.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Company making the announcement
- Peter van der Kuy (person) — Newly appointed Chief Financial Officer
- January 1, 2025 (date) — Effective date of appointment
- Pharming Group N.V. (company) — Previous employer of the new CFO
FAQ
Who has ProQR Therapeutics N.V. appointed as their new Chief Financial Officer?
ProQR Therapeutics N.V. has appointed Peter van der Kuy as their new Chief Financial Officer.
When will Peter van der Kuy's appointment as CFO be effective?
Peter van der Kuy's appointment will be effective on January 1, 2025.
What was Peter van der Kuy's previous role?
Peter van der Kuy previously served as CFO at Pharming Group N.V.
What is the filing type and date?
This is a Form 6-K filed on December 10, 2024.
What is the principal executive office address of ProQR Therapeutics N.V.?
The principal executive offices are located at Zernikedreef 9, 2333 CK Leiden, The Netherlands.
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 9.5 · Accepted 2024-12-10 08:05:16
Filing Documents
- tm2430547d1_6k.htm (6-K) — 12KB
- tm2430547d1_ex99-1.htm (EX-99.1) — 15KB
- 0001104659-24-127017.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PROQR THERAPEUTICS N.V. Date: December 10, 2024 By: /s/ René Beukema René Beukema Chief Corporate Development Officer and General Counsel INDEX TO EXHIBITS Number Description 99.1 Press Release of ProQR Therapeutics N.V. dated December 10, 2024.